About this trial
The objective of this observational study is to analyze the factors influencing wound healing after anal fistula surgery and to assess the effectiveness of interventions in improving overall patient outcomes post-surgery. The primary questions this study aims to answer are:
1. Does the use of the growth factor (New Epi) contribute to accelerating wound healing, reducing the risk of infection, and enhancing patient recovery speed after surgery? 2. Do other factors, such as infection, nutritional status, diabetes, surgical methods, patient age and overall health, immune status, and lifestyle habits, affect the healing of surgical wounds?
Eligibility criteria
Qualifiers
Patients over 18 years old.
Have undergone anal fistula surgery with complete surgical records.
No significant surgical contraindications, such as:Acute infection or inflammation,Severe cardiopulmonary insufficiency,Coagulation disorders,Immunodeficiency,Local skin lesions.
Understand and are willing to participate in the study.Willing to sign the informed consent form.
Disqualifiers
Patients under 18 years of age.
Pregnant or breastfeeding women.
Individuals with pre-existing severe heart, liver, or kidney diseases.
Individuals with active infections or systemic diseases.
Trial design
Treatments tested in this trial
- NewEpi Plus Liquid Wound Dressing
- standard wound care